CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris, a GSK Company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it has completed an agreement with Harvard University to exclusively license two patent applications covering SIRT3-based methods of treatments and assays.
